Genfit Positions To Battle Intercept On Both NASH And PBC Fronts

While beginning to enroll the Phase III trial of elafibranor in NASH, Genfit also plans to study the drug in PBC, an indication in which top competitor Intercept could receive FDA approval this quarter.